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Abstract
Background: Mother-to-child transmission (MTCT) of HIV has been eliminated from the developed world with the
introduction of multi-drug antiretroviral (md-ARV) regimens for the prevention of MTCT (PMTCT); but remains the
major cause of HIV infection among sub-Saharan African children. This study compares two service delivery models
of PMTCT interventions and documents the lessons learned and the challenges encountered during the transition
from single-dose nevirapine (sd-nvp) to md-ARV regimens in a resource-limited setting.
Methods: Program data collected from 32 clinical sites was used to describe trends and compare the performance
(uptake of HIV testing, CD4 screening and ARV regimens initiated during pregnancy) of sites providing PMTCT as a
stand-alone service (stand-alone site) versus sites providing PMTCT as well as antiretroviral therapy (ART) (full
package site). CD4 cell count screening, enrolment into ART services and the initiation of md-ARV regimens during
pregnancy, including dual (zidovudine [AZT] +sd-nvp) prophylaxis and highly active antiretroviral therapy (HAART)
were analysed.
Results: From July 2006 to December 2008, 1,622 pregnant women tested HIV positive (HIV+) during antenatal care
(ANC). CD4 cell count screening during pregnancy increased from 60% to 70%, and the initiation of md-ARV
regimens increased from 35.5% to 97% during this period. In 2008, women attending ANC at full package sites were
30% more likely to undergo CD4 cell count assessment during pregnancy than women attending stand-alone sites
(relative risk (RR) = 1.3; 95% confidence interval (CI): 1.1-1.4). Enrolment of HIV+ pregnant women in ART services was
almost twice as likely at full package sites than at stand-alone sites (RR = 1.9; 95% CI: 1.5-2.3). However, no significant
differences were detected between the two models of care in providing md-ARV (RR = 0.9; 95% CI: 0.9-1.0).
Conclusions: All sites successfully transitioned from sd-nvp to md-ARV regimens for PMTCT. Full package sites offer
the most efficient model for providing immunological assessment and enrolment into care and treatment of HIV+
pregnant women. Strengthening the capacity of stand-alone PMTCT sites to achieve the same objectives is
paramount.
Background
Mother-to-child transmission (MTCT) of HIV remains
the major route of pediatric HIV infection in sub-
Saharan Africa, where over 90% of the 2.1 million chil-
dren living with HIV reside [1-3]. Since 2000, modest
progress has been made towards expanding access to
prevention of MTCT (PMTCT) services in sub-Saharan
Africa. While access to HIV testing during pregnancy
has improved, most PMTCT programs still rely on
administration of single-dose nevirapine (sd-nvp) to
mothers and babies, a simple, inexpensive, but low effi-
cacy antiretroviral (ARV) regimen to reduce the risk of
HIV transmission [3,4]. Since 2004, the World Health
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use of more efficacious multidrug antiretroviral (md-
ARV) regimens for PMTCT, including highly active
antiretroviral therapy( H A A R T )f o rw o m e nw i t h
advanced disease and short course dual prophylaxis for
healthier women not yet eligible for treatment [5]. In
November 2009, the WHO issued revised guidelines
emphasizing the use of md-ARV for PMTCT as well as
the critical need for measuring antenatal CD4 cell
counts to determine HAART eligibility [6]. However,
only 12% and 28% of HIV+ pregnant women in
PMTCT programs received CD4 cell count assessments
in 2007 and 2008, respectively, in low- and middle-
income countries [1,7]. Moreover, the provision of
HAART in antenatal care (ANC) is a challenge due to
maternal and child health (MCH) staff shortages, the
reliance on medical doctors for HAART initiation and
the weak linkages between PMTCT and antiretroviral
therapy (ART) services, which often preclude women
from being fast-tracked into HIV care and treatment
programs [8-11]. Although many sub-Saharan African
countries have introduced md-ARV for PMTCT, little
has been documented about these experiences [10-13].
Rwanda has a generalized HIV epidemic, 3.6% of
women aged 15-49 are living with HIV according to the
Demographic and Health Survey conducted in 2005
[14]. It is estimated that approximately 7,700 newborns
are at risk of acquiring HIV each year [15]. A national
PMTCT program was launched in 1999-2000 at three
pilot sites,[16] and coverage expanded to 285 sites
nationwide by the end of 2007 [17]. In September 2005,
the national PMTCT guidelines were revised to reflect
the WHO recommendations that included more effec-
tive md-ARV regimens [17]. This study compares two
s e r v i c ed e l i v e r ym o d e l sf o rt h eP M T C To fH I Va n d
compares the uptake of HIV testing, CD4 screening and
ARV regimens initiated during pregnancy between 2007
and 2008. It also documents the success of implementa-
tion of the program and the challenges encountered
during the transition from sd-nvp to md-ARV regimens
for PMTCT in 32 sites in Rwanda between July 2006
and December 2008.
Methods
Program description
Since 2004, the International Center for AIDS Care and
Treatment programs (ICAP) of Columbia University,
Mailman School of Public Health (NY, USA), supports
the implementation of HIV prevention, care and treat-
ment programs in Rwanda including capacity building
of staff, on-site mentoring, renovation of infrastructure,
provision of equipment including laboratory machines,
technical support to monitoring and evaluation, and
operational research. In July 2006, ICAP supported the
implementation of PMTCT programs at five health
facilities (sites), including four district hospitals (DHs)
and one health center (HC), and expanded to 32 sites
(four DHs and 28 HCs) by December 2008 in the
Western Province (Kibuye and Gisenyi regions) and
Kigali, the capital city.
PMTCT services are routinely implemented within
MCH services in Rwanda. Opt-out HIV counseling and
testing (CT) is routinely provided in the ANC by trained
nurses using sequential rapid HIV tests following the
national algorithm, with results available the same-day
[18]. Partner testing and couple CT is strongly pro-
moted during pregnancy. The ARV regimens recom-
mended for PMTCT are summarized in Figure 1 [19].
WHO clinical staging and CD4 cell count assessment is
recommended for all HIV-infected pregnant women.
PMTCT staff were trained and mentored to assess the
clinical stage and interpret the CD4 cell count test
results. At the time of writing this report, the prescrip-
tion of HAART for eligible patients was still limited to
trained physicians, mostly working in ART clinics at dis-
trict or referral hospitals, and could not be initiated by
nurses working in PMTCT programs, predominantly at
the HC level.
Two models of PMTCT service delivery were defined:
“full package” s i t e sw h e r eP M T C Ta n dA R Ts e r v i c e s
were both located on the same premises and “stand-
alone” sites where only PMTCT services were available
on-site. Full package and stand-alone sites were author-
ized to provide md-ARV regimens to pregnant women.
However, at the time of writing this report, both stand-
alone and full package sites were providing dual ARV
and the sd-NVP regimens, but only full package sites
offered ‘therapeutic’ HAART and ‘short-course’ HAART
Scenario 1: HIV-infected pregnant women are considered medically eligible for lifelong 
‘therapeutic’ HAART (t-HAART) if they have WHO clinical stage 4 disease or a CD4 cell count 
< 350 cells/mm
3. Recommended regimens: zidovudine (AZT) or stavudine (d4T) + lamivudine 
(3TC) + nevirapine (NVP). 
Scenario 2: Women who present late (> 34 weeks of gestation) are eligible for ‘short-course’ 
HAART (sc-HAART), irrespective of the WHO staging or CD4 cell count. After delivery, 
HAART is discontinued if the CD4 cell count > 350 cells/mm
3 (with a one-week AZT/3TC tail) 
or continued for life if CD4 cell count < 350 cells/mm
3. Recommended regimen: AZT or d4T + 
3TC + NVP. 
Scenario 3: Women, not eligible for HAART, receive short-course AZT (sc-AZT) after 28 weeks 
of gestation, plus SD-NVP at the onset of labor, with a one-week AZT/3TC tail.  
Scenario 4: HIV-negative pregnant women in discordant couples with a HIV-infected partner, as 
well as pregnant women testing HIV positive in the labor room, receive single dose NVP (sd-
NVP in labor with a one-week AZT/3TC tail.  
Scenario 5: Women receiving HAART at the time of conception continue treatment. Efavirenz 
should be avoided in the first trimester. 
All babies of HIV positive mothers receive SD-NVP at birth (within 72 hours) plus four weeks of 
AZT syrup. 
Figure 1 Guidelines for antiretroviral regimens for the
prevention of mother-to-child transmission of HIV in Rwanda,
September 2005.
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sites were initiated as soon as possible during pregnancy
by the ART physician, whereas stand-alone sites referred
HAART-eligible women to the nearest ART site for
enrolment into ART services and the initiation of
treatment.
Immunologic assessment during pregnancy
In 2006, of the five PMTCT sites, only one had the
equipment required to measure CD4 cell counts (FACS-
Count [Becton Dickinson, San Jose, CA, USA]), the
other four sites processed CD4 samples at the nearest
laboratory possessing the necessary equipment. CD4
testing requisition was initially only performed for
patients within ART clinics since a unique patient iden-
tifier (TRACnet number), only provided in the ART
clinic, was required by the lab technician before blood
could be taken. All pregnant women identified in
PMTCT had to be referred to the ART clinic, within
the same premises or via a referral (for stand-alone
sites), to receive a TRACnet ID prior to CD4 testing
requisition. In addition, because most CD4 blood sam-
ples originated from patients in ART services, pregnant
women were therefore asked to come back on a differ-
ent day, generally within a week after receipt of an HIV
positive test result, as this allowed for common batching
of blood samples from patients in ART services.
Between 2007 and 2008, DH supervisors teamed with
mentors from ICAP to support health facilities in asses-
sing and addressing the barriers (Figure 2) to immuno-
logic assessment using an approach described elsewhere
[20]. Figure 2 summarizes the changes recommended
and gradually implemented at district and site levels.
Capacity building for the delivering of multidrug ARV
(md-ARV) regimens initiation during pregnancy
In 2006, few nurses were trained to administer md-ARV
regimens for PMTCT. Refresher training and practical
sessions were organized and 297 staff were trained or
retrained in 32 sites during the period under review. In
each district, the site support staff members worked
with district health teams to provide regular on-site
Challenges identified during sites mentoring Corrective strategies at site, district and national levels
A- Immunologic assessment Facility-based District or national levels
• Limited number of CD4 machines at district level, 
resulting in limited access to CD4 screening by PMTCT 
sites located at health center level.
1- Four district laboratories equipped with CD4 machines and 
staff trained to perform CD4 screening to all patients including 
pregnant women en ANC.
• Efficiency issues for the CD4 testing system at site 
and district levels (Delay between day of HIV testing 
and day of CD4 blood draw, reliance on laboratory 
technician for CD4 blood draw, dependence on ART 
unit for the CD4 code and blood draw for pregnant 
women, turnaround time for CD4 cell count results 
averaging 2-4 weeks)
1- First ANC clinic days re-scheduled to match CD4 
testing days to allow for the same-day point-of-care 
routine blood sample collection for CD4 
assessment in pregnant women
2- PMTCT codes used to label CD4 blood samples 
collected directly by nurses in ANC on the same 
day as HIV diagnosis
1- A coordinated district-wide system for CD4 testing involving 
a network of health centers established around the district 
hospital laboratory (scheduled weekly CD4 sample 
processing), with ongoing quality assurance by the National 
Reference Laboratory
• Reaching and tracing back to care all HIV+ pregnant 
women who had missed a visit
1- Home visits conducted to track women who 
missed appointments
B- Initiation of md-ARV regimens
• Non availability of HAART for eligible women in stand-
alone PMTCT sites
1- The Ministry of Health/TRACPlus authorized stand-alone 
sites to start requesting HAART for pregnant women, but 
treatment initiation remained the responsibility of the visiting 
doctor
• Insufficient capacity to prescribe HAART among 
nurses, and reliance on the phsycian from the district 
hospital for the initiation of HAART even in health 
centers with ART programs
1- Refresher training conducted for all PMTCT health 
care staff 
2- Patients eligible for HAART were escorted to the 
ART clinic and transportation was ensured in stand-
alone sites for long distance referrals
1- Job aids provided to all sites to guide decision making 
regarding HAART-eligibility, and the management of HIV-
infected pregnant women and their infants
2- Regular clinical mentorship visits conducted by the site 
support team with standardized assessment of quality of care
3- Revised and implemented monitoring and evaluation tools 
for longitudinal follow-up of patients (integrated PMTCT care 
components into ANC, maternity and exposed infant follow-
up registers)
• Lack of organized support groups for psychological 
support of pregnant women 
1- Support groups organized for psychosocial support 
and adherence counseling during pregnancy
Figure 2 Challenges and corrective strategies for improving immunologic assessment and initiation of md-ARV regimens during
pregnancy.
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training.
Data collection and statistical analysis
We collected the following routine PMTCT program
indicators from the program monitoring database for the
period July 2006 through December 2008: number of
pregnant women attending first ANC, number of women
known to be HIV positive at first ANC, number of women
tested for HIV, number of women tested HIV positive,
number of male partner counseled and tested for HIV,
number of HIV positive women assessed for CD4 cell
count during pregnancy, number of women who received
CD4 cell count results, number of women with CD4 cell
counts < 350 cells/mm3, number of HIV positive women
enrolled into HIV care and treatment, number of women
with CD4 cell counts < 350 cells/mm3 who initiated
HAART for life ‘therapeutic’ HAART (t-HAART) during
pregnancy, number of women who initiated short-course
HAART (sc-HAART) for prophylaxis during pregnancy,
number of women who initiated dual ARV (AZT/NVP)
prophylaxis during pregnancy, number of women who
received sd-nvp only (sd-NVP) for PMTCT prophylaxis
during pregnancy. These indicators are routinely col-
lected from site registers, and reported monthly to dis-
trict health offices for compilation and transmission to
the central level. In January 2007, the national program
revised the PMTCT program monitoring tools, including
registers and monthly summary forms, adding new indi-
cators for CD4 cell count assessments and enrolment in
HIV care and treatment programs and HAART initiation.
We reported changes over time for each indicator, and
using chi-square tests of association with two-sided p-
values, we compared the performance of the program
across each indicator for the period 2007 - 2008, when
comprehensive PMTCT program data was available.
Finally, we compared the two model of service deliv-
ery (full package vs. stand-alone) across key program
indicators using relative risks (RR) with associated 95%
confidence intervals (CI) for the year 2008 only. The
aggregated format of our data did not allow for control-
ling the effect of clustering across sites. In our analysis,
we defined the following ARV regimens options as
“more efficacious” ARV regimens (dual ARV, HAART
for life, and sc-HAART). Data analysis was conducted
using SAS version 9.1 (SAS Institute Inc., Cary, NC,
USA). The data used for this analysis were aggregated
site level indicators routinely collected by the national
PMTCT program, and therefore did not contain any
patient identifier. This secondary data analysis received
approval from the Columbia University Institutional
Review Board (IRB) and was also granted the non-
research status (exempted from ethical review) by the
Centers for Disease Control and Prevention (CDC),
Atlanta, USA.
Results
HIV testing uptake among pregnant women and male
partners
Between July 2006 and December 2008, 40,674 pregnant
women made a first visit to an ANC and were counseled
for HIV; 99% accepted HIV testing and 4% tested HIV+;
67% male partners also received HIV testing (Table 1).
HIV testing rates, already extremely high at the start of
reporting in 2006, increased from 98% to 99% (p <
0.001) from 2007 to 2008. Partner testing rates also
increased from 57% in 2007 to 75% in 2008 (p <
0.0001).
Immunologic assessment and enrolment in ART services
during pregnancy
Overall, 69% of 2,048 HIV+ (known and newly identified
HIV+) pregnant women were screened for their CD4
cell count during pregnancy, with the proportion
increasing from 60% in 2006 to 70% in 2007 and 2008.
Additional indicators collected in 2007-2008 showed
that 96% of 1,268 women assessed for their CD4 cell
count returned to the health facility to retrieve their
results and 54% of 1,381 HIV+ women identified from
July 2007 through December 2008 were enrolled in
ART services. CD4 cell count screening remained at
70% in 2007 and 2008 (p = 0.18), however, the percen-
tage of women receiving their CD4 test results and
enrolling in HIV care and treatment programs increased
significantly, from 92-98% (p < 0.001) and 41-60% (p =
0.04), respectively (Table 1).
ARV regimens initiated during pregnancy
Between July 2006 and December 2008, 71% of HIV+
pregnant women received an ARV regimen for PMTCT.
The proportion of HIV+ pregnant women initiating
more efficacious md-ARV regimens increased from
35.5% in 2006 to 97% in 2008 and women receiving sd-
nvp decreased from 64.5% to 3% during the same time-
period (Table 1). A total of 292 (24%) women were
eligible for HAART in 2007-2008 based on the Rwandan
national guidelines (CD4 < 350 cells/mm
3), and 83%
initiated HAART during pregnancy. The proportion of
eligible women initiating HAART declined slightly from
86% in 2007 to 79% in 2008 (p = 0.12).
Comparing the models (full package vs. stand-alone site)
of service delivery
By December 2006, 37.5% of PMTCT sites were provid-
ing the full package service and 62.5% were stand-alone
sites; the proportion of full package sites increased to
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with the opening of new PMTCT sites (Table 1).
From January through December 2008, CD4 assess-
ment of HIV+ pregnant women differed across the
models of service delivery with women attending full
package sites 30% more likely to undergo CD4 cell
count assessment than women attending stand-alone
sites [RR = 1.3; 95% CI: 1.1-1.4] (Table 2). Enrolment of
HIV+ pregnant women into ART services was almost
t w i c ea sl i k e l ya tfull package sites than stand-alone
sites [RR = 1.9; 95% CI: 1.5-2.3]. However, no differ-
ences were detected between the two sites, full package
and stand-alone, in initiating treatment for eligible
women determined to be eligible for HAART [RR = 0.9;
95% CI: 0.7-1.1]) and providing more efficacious ARV
regimens [RR = 0.9; 95% CI: 0.9-1.0].
Discussion
Until recently, most PMTCT programs still relied on the
administration of sd-nvp to mothers and babies but md-
ARV regimens have now been implemented. This report
documents the successful implementation of md-ARV
regimens, including HAART, for HIV+ pregnant women
with advanced disease in 32 PMTCT sites in Rwanda.
The transition from sd-nvp to more efficacious regimens
occurred independently of the model of service delivery
(full package vs. stand-alone) within a 30-month period.
T oo u rk n o w l e d g e ,t h i si so n eo ft h ef i r s tr e p o r t st o
comprehensively document the transition from a tradi-
tional sd-nvp regimen to more effective ARV regimens
for PMTCT in a resource-limited setting. Despite
PMTCT service decentralization to health centers with
limited resources and capacities, addressing health
Table 1 HIV testing, CD4 cell count assessment, and ARV regimens initiated during pregnancy in Rwanda, from July
2006 through to December 2008 (N= 32 sites)
2006
(Jul-Dec)
N (%)
2007
N (%)
2008
N (%)
Total
N (%)
p**
(2007 vs.
2008)
Total number of sites 14 19 32 - -
Full package 5 (35.7%) 15 (79%) 18 (56%) - -
Counseling and testing of pregnant women in ANC:
First ANC visit 4,520 15,469 20,685 40,674 -
Known to be HIV positive NA 135 (0.9%) 291 (1.4%) 426 (1%) -
Tested for HIV 4,452
(98%)
15,231 (98%) 20,564 (99%) 40,247 (99%) <0.0001
Tested HIV positive 234 (5%) 741 (5%) 647 (3%) 1,622 (4%) <0.0001
Partner counseling and HIV testing NA 8,652 (57%) 15,463 (75%) 24,115 (67%)
$ <0.0001
CD4 cell count assessment during pregnancy
Total HIV positive in ANC 234 876 938 2,048 -
Screened for CD4 cell counts
¶ 140 (60%) 610 (70%) 658 (70%) 1,408 (69%) 0.81
Received CD4 cell count results
¶¶ NA 564 (92%) 647 (98%) 1,211 (96%)
$ <0.0001
CD4 cell counts < 350 cells/mm
3 NA 132 (23%) 160 (25%) 292 (24%)
$ 0.59
Enrolment of HIV positive women into care and treatment NA 180/443
(41%)
@
564/938
(60%)
744/1381
(54%)
$
-
HAART initiation for women with CD4 cell counts < 350 cells/mm
3 NA 114/132 (86%) 127/160
(79%)
241/292 (83%)
$ 0.12
Total HIV positive in ANC 234 876 938 2,048
All ARV regimens initiated during pregnancy 155 (66%) 667 (76%) 638 (68%) 1460 (71%)
Dual (AZT/NVP) prophylaxis 55 (35.5%) 386 (58%) 403 (63%) 844 (58%)
HAART for life NA 114 (17%) 127 (20%) 241 (16%)
sd-nvp only 100
(64.5%)
34 (5%) 21 (3%) 155 (11%)
Short-course HAART NA 133 (20%) 87 (14%) 220 (15%)
More efficacious ARV regimens (dual ARV, or HAART for life or sc-
HAART)
55 (35.5%) 633 (95%) 617 (97%) 1325 (89%)
$ Percentage calculated based on 2007 and 2008 data only.
NA indicates data not available or not routinely reported in the program monthly report.
¶ Indicates the number of HIV+ pregnant women giving blood for CD4 testing and includes women of known HIV+ status.
¶¶ Indicates the number of HIV+ women receiving CD4 results in a given period and might include women screened in a previous time period. This number is
used as a denominator to compute the proportion of women with CD4 cell counts < 350 cells/mm
3, which reflects the number of women whose results were
available and who returned for enrolment in health regimens and subsequent HAART initiation.
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increased numbers of HIV+ women undergoing an
immunologic assessment during pregnancy, and
improved identification of pregnant women who were
eligible for therapy and subsequently initiated on
HAART in both full package and stand-alone sites.
However, more effort is needed to ensure effective
CD4+ cell count assessments and the enrolment of
HIV+ women in ART services in stand-alone sites. The
finding of such studies will be useful in the design of
strategies for implementing the 2009 WHO recommen-
dations into national PMTCT programs.
The number of HIV+ pregnant women who were
screened for CD4 cell counts during pregnancy (up to
70% in 2008) and who received their results (up to 98%
in 2008) significantly increased following the introduc-
tion of changes to the CD4 testing system at both the
site and district levels. One major innovation was the
same-day point-of-care blood sample taken from HIV+
pregnant women in ANC clinics. The importance of
same-day CD4 cell count testing was also highlighted in
two studies from South Africa reporting an uptake rate
of over 97% for CD4 cell count screening during preg-
nancy [10,11]. Although most sites in this program sent
samples to off-site laboratories mainly at the DH level
for CD4 measurement, it could be anticipated that with
the implementation of a weekly sample processing sys-
tem, the turnaround time for CD4 cell count results
would be reduced. Our data further suggested that
despite the improvements in CD4 cell count assessments
over time, women in full package sites were more
likely to undergo immunologic screening than those in
stand-alone sites. Although our study did not investi-
gate the reasons for such a difference, it could be
hypothesized that in 2008 the addition of 13 new
stand-alone sites, which likely possessed ineffective
CD4 testing systems, reduced the overall performance
of stand-alone sites.
We found that approximately one quarter of pregnant
women were eligible for HAART, based on CD4 cell
counts ≤ 350 cells/mm
3. This is two-fold lower than the
55% reported in a study in the Western Cape, South
Africa,[11] suggesting that most pregnant women are
diagnosed earlier in the course of HIV infection in our
clinical settings. In addition, in our findings, a high pro-
portion (85%) of eligible pregnant women initiated
HAART with no significant differences between the
models of service delivery. Although women in full
package s i t e sw e r em o r el i k e l yt ou n d e r g oC D 4t e s t i n g ,
women who received testing and were determined to be
eligible were just as likely to initiate HAART in stand-
alone s i t e sa si nfull package sites in 2008, suggesting
that the changes that were introduced had a positive
impact, as summarized in Figure 2.
In our report, the uptake of HAART among women
identified as eligible was found to be higher than the 51%
reported in five sites in the Western Cape [11] and the
75% reported in Gauteng province, [10] South Africa.
Similar to the findings in the Western Cape, our study
revealed that the model of service delivery did not
Table 2 CD4 cell count assessment, enrolment into care and treatment and ARV initiated during pregnancy among
HIV positive women according to the type of HIV services package, Rwanda, from January through December 2008
Full package
$ Stand-alone RR (95% CI)
#
Sites, N (%) 18 (56%) 14 (44%) -
Total HIV positive pregnant women (N) 743 195 -
CD4 cell count assessment, N (%):
Screened for CD4 cell counts
¶ 547 (74%) 111 (57%) 1.3 (1.1 - 1.4)
Received CD4 cell count result
¶¶ 536 (98%) 111 (100%) 0.97 (0.96 - 1.0)
CD4 cell count < 350 cells/mm
3 134 (25%) 26 (23%) -
Enrolment into care and treatment, N (%) 495 (67%) 69 (35%) 1.9 (1.5 - 2.3)
HAART initiation among women with CD4 cell counts < 350 cells/mm
3, N (%) 105 (78%) 22 (85%) 0.9 (0.7 - 1.1)
Received PMTCT prophylaxis or
more efficacious ARV regimens:
511 (96%) 106 (100%) 0.9 (0.9 - 1.0)
Dual (AZT/sd-nvp) prophylaxis 331 (62%) 72 (68%) -
HAART for life 105 (20%) 22 (21%) -
Short-course HAART 75 (14%) 12 (11%) -
sd-nvp only 21 (4%) 0 (0%) -
$ Full package sites provide comprehensive PMTCT and on-site ART services.
¶ The number of HIV+ pregnant women who underwent the CD4 test, including women tested in ANC and those of known HIV+ status who had not initiated
HAART before their current pregnancy.
¶¶ The number of HIV+ women receiving CD4 results in a given quarter, including all women who received their results at a follow-up visit during the quarter.
This number includes women tested in previous quarters who retrieved their CD4 counts during the indicated quarter.
# Relative Risk (RR) comparing the full package service (PMTCT and ART) as a reference to the stand-alone service; CI: confidence interval.
Tsague et al. BMC Public Health 2010, 10:753
http://www.biomedcentral.com/1471-2458/10/753
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[11]. The high uptake of HAART among eligible women
identified in our study might be attributable to a number
of innovations including improved psychosocial support,
escorting eligible women to the ART clinic and liaising
with social workers to track women who missed appoint-
ments. A tracking system for pregnant women was
deemed more feasible in our setting given the small num-
ber of HAART-eligible women compared with a higher
prevalence setting like South Africa. Furthermore, denial
and fear of disclosure to sexual partners was reported as
a limiting factor for effective treatment in South Africa,
whereas the high rate of partner testing and the roll-out
of psychosocial support structures (e.g., associations of
people living with HIV and AIDS, and support groups for
HIV+ patients) over the past two years could have miti-
gated the impact of this factor in our setting. Finally,
according to the 2008 Rwanda Interim Demographic and
Health (I-DHS) survey, about 96% of pregnant women
attend at least one ANC visit during their pregnancy;
most of them attending ANC for the first time before the
end of the second trimester, giving enough time for those
women tested HIV infected to start the ARV prophylaxis
or treatment.
Health care providers in full package sites may be
prompted to actively enroll women found to be eligible
for HAART in the ART program, given that HAART
initiation could be done in the same facility. We could
hypothesize therefore, that making HAART available in
stand-alone sites and accessible for eligible pregnant
women may provide a motivation for providers to
undertake CD4 cell count screening and enroll HIV+
and eligible pregnant women into ART services. By
doing so, it would further reduce the burden on preg-
nant women who were asked to travel, in some cases,
long distances to reach the nearest ART site.
We noted, however, that the two models of service
delivery did not differ with regard to HAART initiation
among eligible pregnant women. This results from the
effective system for referral of eligible pregnant women
from stand-alone sites to the nearest full package site,
coupled with the availability of doctors from the DH
who usually visit full package sites on a weekly basis for
HAART initiation among new HIV+ patients. As
PMTCT services continue to be scaled-up at the district
level, the “flying doctors” approach might not be cost-
effective and sustainable in resource limited settings.
Task-shifting HAART initiation to nurses is therefore
necessary and this has been successful performed in var-
ious settings [21-24]. Rwanda adopted in 2009 a national
policy on task-shifting for HIV services and its imple-
mentation will contribute to improve and sustain the
timely initiation of HAART, particularly among eligible
HIV+ pregnant women.
Some key factors for an effective transition from sd-
nvp to md-ARV regimens include among others the
capacity building and regular mentoring of nurses, the
routine assessment of the quality of care provided by
nurses during the transition to md-ARV regimens, the
full integration of PMTCT care components into MCH
services, the strengthening of the CD4 testing capacity
at district level, the reorganizing of services at site level
with an emphasis on effective linkages between PMTCT
and ART services, and the high level commitment and
leadership of the Rwandan government’s to improving
maternal and child survival, including virtual elimination
of pediatric HIV infection.
The analysis carried out in this study was subject to
some limitations. A recent analysis of routine PMTCT
data in South Africa concluded that there were major
weaknesses in the completeness and accuracy of this
data which precluded its use in the tracking of process
performance of facilities,[25] however, we believe that
the routine PMTCT data in Rwanda is of good quality
due to the implementation of a rigorous quality assur-
ance process whereby aggregate reports are verified
against program registers each month by site support
staff. In addition, by focusing the analysis on antenatal
services, findings are limited to the initiation of PMTCT
regimens during pregnancy, and do not address mater-
nal adherence to ARV regimens during pregnancy,
maternal and infant ARV uptake at delivery, or the over-
all impact of PMTCT interventions on maternal and
child health. Also, the improvements introduced in the
routine data collection system in 2007 have likely
increased reporting on the uptake of various PMTCT
interventions, compared with 2006. We were unable to
account for clustering of patients within clinics in our
analysis, thus underestimatin gt h ev a r i a n c ea s s o c i a t e d
with each program indicator. Finally, since several inter-
ventions occurred simultaneously, it is difficult to deter-
mine the relative importance of each intervention on
program performance.
Conclusions
This report has demonstrated that regardless of the
model of PMTCT service delivery, it is feasible to transi-
tion from sd-nvp regimen to more effective md-ARV
regimen in a resource limited, public sector PMTCT
program. However, more efforts are needed to ensure
effective CD4+ cell count assessment and the enrolment
o fH I V +w o m e ni nA R Ts e r v i c e si nstand-alone sites,
and task-shifting is necessary to ensure the timely initia-
tion and follow-up of HAART among pregnant women.
These findings provide valuable insight which can be
applied to the design of effective service delivery models
for the transition from sd-nvp to md-ARV within
national PMTCT programs in resource limited settings,
Tsague et al. BMC Public Health 2010, 10:753
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